Cagrilintide 5mg (10 vials/Kit): Long-Acting Amylin Receptor Agonist for Metabolic Research

Cagrilintide is an acylated, long-acting non-selective amylin receptor agonist (AMYR) engineered specifically for advanced endocrine, metabolic, and obesity research models. Operating as a synthetic analog of human amylin (islet amyloid polypeptide or IAPP), Cagrilintide potentates signaling across calcitonin receptors (CTR) and amylin receptor subtypes AMY1, AMY2, and AMY3. Sourcing Cagrilintide 5mg (10 vials/Kit) provides biotechnology institutions, academic laboratories, and clinical researchers with a standardized, high-purity analytical reagent designed to investigate central satiety signaling, delayed gastric emptying, glucagon suppression, and multi-pathway weight management dynamics.

In modern metabolic research, native human amylin exhibits a exceptionally short biological half-life and a strong propensity to aggregate into toxic amyloid fibrils, making continuous infusion necessary for in vitro and in vivo studies. Cagrilintide overcomes these biochemical hurdles through specific amino acid substitutions and a lipophilic C18 fatty diacid side-chain modification. This acylation enables reversible binding to serum albumin, protecting the peptide against enzymatic cleavage and renal clearance. When evaluating neuroendocrine hunger circuits or combination metabolic therapies (such as co-formulations with GLP-1 or GIP receptor agonists like Semaglutide or Tirzepatide), utilizing high-grade Cagrilintide 5mg (10 vials/Kit) guarantees prolonged receptor coverage and reproducible biological responses.

Maintaining exact batch consistency and reagent stability is paramount for quantitative energy expenditure and nutrient partitioning assays. The Cagrilintide 5mg (10 vials/Kit) packaging configuration delivers 50mg of total high-purity active material distributed across ten individual 5mg USP Type I borosilicate glass vials. Lyophilized under sterile vacuum conditions, each vial contains a uniform, highly stable powder cake. This modular multi-vial system allows laboratory staff to reconstitute only the active working stock required for immediate experimental protocols, preserving remaining vials under deep freeze stasis and eliminating structural loss caused by repeated freeze-thaw cycles.

Receptor Agonism, Satiety Signaling, and Technical Specifications of Cagrilintide 5mg (10 vials/Kit)

The primary bioactivity of Cagrilintide 5mg (10 vials/Kit) stems from its dual agonism at central and peripheral amylin/calcitonin receptors, which are richly expressed in the area postrema (AP) and nucleus of the solitary tract (NTS) within the hindbrain:

• Central Satiety & Appetite Suppression: Activates hindbrain AMY receptor networks to suppress homeostatic and hedonic food intake pathways, modulating neuronal firing in the arcuate nucleus (ARC) independently of leptin or insulin pathways.

• Gastric Motility & Nutrient Absorption Kinetics: Potently delays gastric emptying rate and inhibits postprandial glucagon secretion, leading to flattened postprandial glucose excursions in metabolic models.

• Synergistic Incretin Co-Stimulation: Demonstrates supra-additive weight-loss and glycemic modulation when co-administered with GLP-1 and GIP receptor agonists in preclinical dual-mechanism (e.g., “CagriSema”) research models.

• Enhanced Chemical Stability & Fibrillation Resistance: Structural modifications prevent self-aggregation and fibril formation, preserving peptide solubility in aqueous solutions.

• Ultra-High Chemical Purity ($\ge$99.0%): Synthesized via automated Solid-Phase Peptide Synthesis (SPPS) and purified using preparative High-Performance Liquid Chromatography (HPLC) to guarantee the complete removal of truncated fragments and manufacturing impurities.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols for Cagrilintide 5mg

Achieving reproducible, publication-grade results when working with Cagrilintide 5mg (10 vials/Kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage procedures. Fatty-acid acylated peptides require deliberate, gentle reconstitution to prevent foam formation and ensure complete solution clarity.

Perform all preparation steps inside a certified Class II Biosafety Cabinet or laminar flow workspace:

1. Temperature Equilibration: Allow the frozen Cagrilintide 5mg (10 vials/Kit) vial to adjust to ambient room temperature prior to solvent introduction to prevent condensation inside the glass vial.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the desired volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS, pH 7.4). Incline the vial at a 45-degree angle and slowly direct the liquid stream down the inner glass wall so it trickles gently over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully saturate the powder cake for 2–3 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until the solution becomes completely clear and colorless. Never vortex or shake vigorously, as turbulent agitation can induce peptide shearing and foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide the reconstituted solution into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of Cagrilintide 5mg (10 vials/Kit) undergoes third-party analytical verification. High-Performance Liquid Chromatography (HPLC) chromatograms confirm individual component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: Cagrilintide 5mg (10 vials/Kit) is manufactured, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. Cagrilintide 5mg (10 vials/Kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.